Our Emergency Care Trials
CRASH-2 (complete)
Results showed that tranexamic acid safely reduced the risk of death in bleeding trauma patients
CRASH-3 (complete)
The CRASH-3 trial is the first evidence of a drug which can prevent death following Traumatic Brain Injury (TBI)
CRASH-4 (Pilot Study - ongoing)
The effects of early intramuscular (IM) tranexamic acid (TXA) treatment on dementia, disability and death in older adults with mild traumatic brain injury (TBI)
CRASH-19 (recruitment not started)
Aim to assess the effectiveness and safety of supportive care interventions for patients hospitalised with suspected or confirmed acute COVID-19 infection with a focus on cardiac and pulmonary protection. We will evaluate the effects of aspirin, the angiotensin receptor blocker losartan, and simvastatin compared with standard care.
** Recruitment not started due to lack of funding**
BRAIN Trial (complete)
Bradykinin B2 Receptor Antagonist (Anatibant) in Neurotrauma: A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury
Halt-IT (complete)
The HALT-IT trial assessed whether administration of tranexamic acid (TXA) in people with acute gastrointestinal bleeding can reduce their risk of dying in hospital
Trauma - INTACT (complete)
Trauma-INTACT results show that TXA is well tolerated and rapidly absorbed via the IM route in bleeding trauma patients
WOMAN Trial (complete)
Tranexamic acid for the treatment of postpartum haemorrhage: An international, randomised, double blind, placebo controlled trial. The WOMAN trial showed that if given within 3 hours, TXA can reduce the risk of death due to bleeding by one third
Are you interested in collaborating on one of our ongoing trials? Email enquiries to lshtmctu@lshtm.ac.uk
Our Funders
